Elia Seguí, MD

Medical Oncologist | Research fellow @DFCI_BreastOnc | PhD student Translational Genomics @idibaps | @SOLTIyoung member | 🧬 Main focus: IO&breast cancer

[Sara Tolaney @stolaney1]

We are so incredibly lucky to work with the superstar @tess_omeara! She is multitalented-- an incredible colleague, absolutely wonderful with patients, and able to analyze complex single-cell data!

@DFCI_BreastOnc

[Elia Seguí, MD @elia_segui]

@michelle_li 💥💥

[Judith Agudo @JudithAgudo1]

Metastasis kills most cancer patients and grows from invisible seeds. How do these seeds escape from attack by immune cells? These seeds harness stress hormones!🤯
⁦thanks to ⁦@nyscf⁩ ⁦@parkerici⁩ for their support. Today at ⁦@Nature⁩ https://t.co/rMKnHEqQwb

[Dana-Farber’s Breast Oncology Center @DFCI_BreastOnc]

New 📰: Pembrolizumab and Paclitaxel in HR+/HER2- #BreastCancer with HER2-Enriched or Basal-Like Subtypes
🔓https://t.co/joSp1J0F4q
@BenedettaConte5 @fara_bm @TomasPascualMD @CHernandoM @MOliveira_MD @MuozMateu @elia_segui @AdelaRodrguezH1 @G_Villacampa @AnaVivancosVHIO @CCR_AACR

[SOLTI #cancerresearch @_SOLTI]

Today, let’s talk triple-negative breast cancer 🎬

In this third video of SOLTI Young Perspectives, experts Elia Seguí (@elia_segui), MD (Dana-Farber Cancer Institute, 4CB) and Rodrigo Sánchez-Bayona (@Rodrosb), MD PhD (Hosp Univ 12 Octubre) share the latest updates, challenges, and controversies in this field.

Find out more on our YouTube channel 🔗 https://t.co/lKsCqVomeG

This project is supported by a grant from Daiichi-Sankyo Europe GmbH (@EUdaiichisankyo) 

#beSOLTI #SYPerspectives #SABCS25 #breastcancer

[SOLTI #cancerresearch @_SOLTI]

Insights, debates, and practical takeaways, brought to you by SOLTI Young Perspectives! 🎬

Today, Elia Seguí (@elia_segui), MD  (Dana-Farber Cancer Institute, 4CB) and Benjamin Walbaum (@benjiwal), MD (Hospital Clínico Universidad Católica de Chile) engage in an insightful discussion on luminal breast cancer treatment.

Don’t miss the full conversation 🔗 https://t.co/22Lhkeanrt 

This project is supported by a grant from Daiichi-Sankyo Europe GmbH

#beSOLTI #SYPerspectives #SABCS25 #breastcancer

[Carmine Valenza @ValenzaCarmine]

Today is THE day!

The post-SABCS 2025 talk by @DrHBurstein at @DFCI_BreastOnc just started!

[Philippe Aftimos, MD  @aftimosp]

@PTarantinoMD @TumorBoardTues @MPishvaian @elia_segui @IntegrityCE @elmayermd @MichaelGnant @CCortiMD TMB not infrequent in ILC and at least more frequent than IDC-NST. Not confident however about TMB and IO in breast cancer. My limited clinical experience has been disappointing…

https://t.co/q6R00ZUoaF

[Elia Seguí, MD @elia_segui]

@TumorBoardTues @PTarantinoMD @IntegrityCE @elmayermd @MichaelGnant @CCortiMD #PostTest Q2️⃣ #TumorBoardTuesday
👉🏽 Free CME 🔗 https://t.co/hD1RhES9Ih

Analyses of data from adjuvant studies of abemaciclib or ribociclib suggest that dose reductions have which of the following effects on efficacy?

[Elia Seguí, MD @elia_segui]

@TumorBoardTues @PTarantinoMD @IntegrityCE @elmayermd @MichaelGnant @CCortiMD #PostTest Q1️⃣ #TumorBoardTuesday
👉🏽#CME Eval 🔗 https://t.co/1UpEuewql1
👉🏽ALL CME🔗 https://t.co/hD1RhES9Ih

Your pt is a postmenopausal ♀️w/ g3 T2N1 ER+/PR+/HER2- IDC s/p BCS, adjuvant CT and RT. Which of the following is an approved therapeutic option for this patient?

[Elia Seguí, MD @elia_segui]

@TumorBoardTues @PTarantinoMD @IntegrityCE @elmayermd @MichaelGnant @CCortiMD 32/32 #TumorBoardTuesday

🔑Messages
🔹Mgmt after adj CDK4/6i→unclear
🔹Tumor bx @ relapse→essential (ER/HER2, NGS)
🔹Biology & timing of relapse should guide tx
🔹Options: novel SERDs, AKT/PI3K tx, ADCs, trials, et al
🔹Future trials must stratify by prior adj CDK4/6i exposure

[Elia Seguí, MD @elia_segui]

@TumorBoardTues @PTarantinoMD @IntegrityCE @elmayermd @MichaelGnant @CCortiMD 31/32 #TumorBoardTuesday #bcsm

🧐 Q: How would you treat this patient❓

⬇️ Vote and discuss

[Elia Seguí, MD @elia_segui]

@TumorBoardTues @PTarantinoMD @IntegrityCE @elmayermd @MichaelGnant @CCortiMD 30/32 #TumorBoardTuesday #bcsm

👩‍⚕️Back to our case…
📋 Relapse biopsy:
🔹ILC, Gr 2
🔹ER 5%, PR 0%, HER2 IHC 0
🔹PD-L1 CPS 2
🔹NGS: CDH1, PIK3CA, TP53m
🔹TMB: 24 mut/Mb

[Elia Seguí, MD @elia_segui]

@TumorBoardTues @PTarantinoMD @IntegrityCE @elmayermd @MichaelGnant @CCortiMD 29/32 #TumorBoardTuesday

🧑‍🏫Mini Tweetorial🧑‍🏫
🌍RWD: Relapse after adj abema: clinical behavior
Median duration of 1L metastatic tx: 3 mo (IQR 1.6–5.0)
➡️ Suggests aggressive biology & endocrine resistance

🔗https://t.co/x5cJhILxIp

[Elia Seguí, MD @elia_segui]

@TumorBoardTues @PTarantinoMD @IntegrityCE @elmayermd @MichaelGnant 28/32 #tumorboardtuesday

🧑‍🏫Mini Tweetorial🧑‍🏫
Relapse after adj abema: What now? @CCortiMD

🌍RWD
🔹Recurrence after adj abema+ET ~9%
🔹Phenotypic shift: ~50% of pts w/ paired samples showed ER loss @ recurrence
🔹@ relapse
-- TP53 pathway alt 90% (9/10)
-- ESR1m 1%
-- No RB1m

[Elia Seguí, MD @elia_segui]

@TumorBoardTues @PTarantinoMD @IntegrityCE @elmayermd @MichaelGnant 27/32 #TumorBoardTuesday

🧐 Q: What is your next step❓

⬇️ Vote & discuss

[Elia Seguí, MD @elia_segui]

@TumorBoardTues @PTarantinoMD @IntegrityCE @elmayermd @MichaelGnant 26/32 #TumorBoardTuesday
👩‍⚕️Back to our case…
18 mo into adj OFS+AI+abema w/ good tolerability, pt develops new cough

🫁 CT scan shows:
🔹Lung lesions
🔹Mediastinal lymphadenopathy
🔹Bone mets

[Elia Seguí, MD @elia_segui]

@TumorBoardTues @PTarantinoMD @IntegrityCE @elmayermd @MichaelGnant 25/32 #TumorBoardTuesday

🧑‍🏫Mini Tweetorial🧑‍🏫
📊 monarchE ctDNA-MRD (exploratory)
N=910; sampling BL, 3, 6, 24 mo
📈 Prognosis by ctDNA:
🔹 Persistently ctDNA–: 4y iDFS 88%
🔹 ctDNA+ → ctDNA–: 58%
🔹 Persistently ctDNA+ or –→+: 11%

🔗 https://t.co/zaVIvWbENn

[Elia Seguí, MD @elia_segui]

@TumorBoardTues @PTarantinoMD @IntegrityCE @elmayermd @MichaelGnant 24/32 #TumorBoardTuesday

🧑‍🏫Mini Tweetorial🧑‍🏫
🧬ctDNA/MRD: Future of selection?
🔹In eBC, ctDNA/MRD detection is strongly associated with recurrence
🔹But, benefit of intervening based on ctDNA/MRD unproven
🤔Can ctDNA help ID pts who may still do very well with ET alone?

[Elia Seguí, MD @elia_segui]

@TumorBoardTues @PTarantinoMD @IntegrityCE @elmayermd @MichaelGnant 23/32 #TumorBoardTuesday #bcsm

🧐 Q: In your opinion, what strategy holds the most promise to refine adj CDK4/6i selection & minimize overtreatment❓

⬇️ Vote & discuss